JP2020510028A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510028A5
JP2020510028A5 JP2019548709A JP2019548709A JP2020510028A5 JP 2020510028 A5 JP2020510028 A5 JP 2020510028A5 JP 2019548709 A JP2019548709 A JP 2019548709A JP 2019548709 A JP2019548709 A JP 2019548709A JP 2020510028 A5 JP2020510028 A5 JP 2020510028A5
Authority
JP
Japan
Prior art keywords
nausea
delivery device
drug delivery
inducing
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019548709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/021594 external-priority patent/WO2018165462A1/en
Publication of JP2020510028A publication Critical patent/JP2020510028A/ja
Publication of JP2020510028A5 publication Critical patent/JP2020510028A5/ja
Priority to JP2023007454A priority Critical patent/JP2023061945A/ja
Pending legal-status Critical Current

Links

JP2019548709A 2017-03-08 2018-03-08 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法 Pending JP2020510028A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023007454A JP2023061945A (ja) 2017-03-08 2023-01-20 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468399P 2017-03-08 2017-03-08
US62/468,399 2017-03-08
PCT/US2018/021594 WO2018165462A1 (en) 2017-03-08 2018-03-08 Apparatus and methods for administration of a nauseogenic compound from a drug delivery device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023007454A Division JP2023061945A (ja) 2017-03-08 2023-01-20 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法

Publications (2)

Publication Number Publication Date
JP2020510028A JP2020510028A (ja) 2020-04-02
JP2020510028A5 true JP2020510028A5 (https=) 2021-04-22

Family

ID=61692164

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548709A Pending JP2020510028A (ja) 2017-03-08 2018-03-08 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
JP2023007454A Pending JP2023061945A (ja) 2017-03-08 2023-01-20 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023007454A Pending JP2023061945A (ja) 2017-03-08 2023-01-20 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法

Country Status (10)

Country Link
US (1) US20200188479A1 (https=)
EP (1) EP3592376A1 (https=)
JP (2) JP2020510028A (https=)
KR (1) KR20190126335A (https=)
CN (1) CN110545838A (https=)
AU (1) AU2018231249A1 (https=)
CA (1) CA3055759A1 (https=)
IL (1) IL269001A (https=)
MX (1) MX2019010651A (https=)
WO (1) WO2018165462A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
JP2023522944A (ja) * 2020-04-20 2023-06-01 アイツーオー・セラピューティクス・インコーポレイテッド １型糖尿病患者に優れた血糖制御をもたらすためのヒトアミリンアナログポリペプチドの使用
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
US20250268231A1 (en) * 2024-02-27 2025-08-28 Ashop Commerce Pty Ltd. System and method for monitoring and controlling pet activity

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK155694A3 (en) * 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
ES2233768T3 (es) 1996-02-02 2005-06-16 Alza Corporation Liberacion prolongada de un agente activo utilizando un sistema implantable.
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ES2182379T3 (es) 1997-12-22 2003-03-01 Alza Corp Membrana de regulacion del regimen de liberacion para dispositivos de administracion controlada de farmacos.
JP4173635B2 (ja) 1997-12-29 2008-10-29 インターシア セラピューティクス，インコーポレイティド 膜プラグ保持機構を有する浸透供給装置
WO1999033449A1 (en) 1997-12-30 1999-07-08 Alza Corporation Beneficial agent delivery system with membrane plug
JP2002512175A (ja) * 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
JP4383674B2 (ja) 1998-12-31 2009-12-16 インターシア セラピューティクス，インコーポレイティド 空間効率のよいピストンを有する浸透圧送達システム
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
CA2402637C (en) 1999-12-21 2007-04-10 Alza Corporation Valve for osmotic devices
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
MXPA05000224A (es) 2002-06-26 2005-06-03 Alza Corp Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
ATE387236T1 (de) 2003-03-31 2008-03-15 Alza Corp Osmotische pumpe mit mitteln zum ableiten des innendrucks
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CA2595457A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
ES2736184T3 (es) 2005-08-19 2019-12-26 Amylin Pharmaceuticals Llc Exendina para el tratamiento de la diabetes y la reducción del peso corporal
ES2495741T3 (es) * 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
SMT201700583T1 (it) * 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
EP2512518A1 (en) * 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
CA3070513C (en) * 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013083826A2 (en) * 2011-12-09 2013-06-13 Novo Nordisk A/S Glp-1 agonists
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
US10479868B2 (en) * 2014-09-04 2019-11-19 Nano Precision Medical, Inc. Polymeric stabilizing formulations
RU2760007C2 (ru) * 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
WO2017200944A1 (en) * 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
CN110225762A (zh) * 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Similar Documents

Publication Publication Date Title
AU2002318211B2 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
JP2020510028A5 (https=)
AU2002318211A1 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
CN112512633A (zh) 使用gip/glp1共激动剂用于治疗的方法
IL312012A (en) Compositions and methods for the treatment of opioid overdose
JP2019515899A5 (https=)
US20150094259A1 (en) Transdermal Delivery Devices
RU2013133803A (ru) Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
RU2015101826A (ru) Применение долгодействующих пептидов glp-1
JP2014524480A5 (https=)
JP2015501314A (ja) ２型糖尿病の治療プロトコル
JP2015520188A5 (https=)
US10080747B2 (en) Nicotinic attenuation of CNS inflammation and autoimmunity
RU2011105029A (ru) Доставка октреотида из сухих лекарственных форм
KR20130113443A (ko) 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도
JP2014514289A (ja) ２型糖尿病患者における低血糖症の予防
EP4198059A1 (en) Modulation of cellular stress
CN106459971B (zh) 用于治疗自身免疫性疾病的联合疗法
US20180092965A1 (en) Treatment Type 2 Diabetes Mellitus Patients
CA3133084A1 (en) Formulation including a combination of .beta.-endorphin and adrenocorticotropic hormone
WO1994014462A1 (en) Method of retarding the progression of chronic renal failure
JP2020500864A5 (https=)
KR20250029908A (ko) 티르제파티드 조성물 및 용도
Shaw et al. Metabolic intervention in surgical patients. An assessment of the effect of somatostatin, ranitidine, naloxone, diclophenac, dipyridamole, or salbutamol infusion on energy and protein kinetics in surgical patients using stable and radioisotopes
WO2011112167A1 (en) Compositions and methods for diabetes treatment